Okay, let's tackle this question. The user wants me to create a detailed explanation for a multiple-choice question about rivastigmine. The question is asking which drug, when combined with rivastigmine, would decrease its efficacy. First, I need to recall what rivastigmine is used for and its mechanism.

Rivastigmine is a cholinesterase inhibitor, primarily used in Alzheimer's treatment. It works by inhibiting acetylcholinesterase, increasing acetylcholine levels in the brain. Now, the question is about drug interactions that reduce its efficacy. So, I need to think about drugs that might interfere with this mechanism.

Possible interactions could involve drugs that also affect cholinergic pathways. For example, anticholinergic drugs would counteract rivastigmine's effect. Anticholinergics like atropine or benztropine block acetylcholine receptors, so taking them with rivastigmine would reduce the drug's effectiveness. Alternatively, maybe something that induces liver enzymes, increasing rivastigmine's metabolism. But rivastigmine is primarily metabolized by butyrylcholinesterase, so enzyme inducers like rifampin might be a factor. Wait, but the main interaction is probably anticholinergics.

Looking at the options, if one of them is an anticholinergic, that would be the correct answer. Let's say the options include drugs like benztropine. The other options might be things like SSRIs, beta-blockers, or other cholinesterase inhibitors. Those wouldn't interfere. So the correct answer is the anticholinergic drug. Now, the explanation should cover the mechanism, why anticholinergics are antagonists, and why others aren't. Also, mention the clinical pearl about avoiding anticholinergics with cholinesterase inhibitors.

**Core Concept**
Rivastigmine is a reversible cholinesterase inhibitor used in Alzheimer’s disease to increase acetylcholine availability. Its efficacy depends on uninterrupted cholinergic signaling, which can be antagonized by drugs with anticholinergic properties.

**Why the Correct Answer is Right**
Anticholinergic drugs (e.g., **benztropine**) competitively block acetylcholine receptors, counteracting rivastigmine’s mechanism of action. By inhibiting cholinergic neurotransmission, they reduce the therapeutic effect of cholinesterase inhibitors, worsening cognitive outcomes in Alzheimer’s patients. This pharmacodynamic antagonism is dose-dependent and clinically significant.

**Why Each Wrong Option is Incorrect**
**Option A:** SSRIs (e.g., sertraline) do not interfere with cholinergic pathways.
**Option B:** Beta-blockers (e.g., metoprolol) act on adrenergic receptors and have no direct impact on acetylcholine.
**Option D:** NMDA antagonists (e.g., memantine) work synergistically with cholinesterase inhibitors, enhancing their efficacy.

**Clinical Pearl / High-Yield Fact**
Always avoid concurrent use of anticholinergic medications (e.g., benztropine, atropine) with cholinesterase inhibitors like rivastigmine. This is a classic exam trap—students often confuse synergistic vs. antagonistic drug interactions in neurodegenerative diseases.

✓ Correct Answer: C. Tricyclic antidepressants